Literature DB >> 11689042

The Epstein-Barr virus encoded latent membrane protein 2A augments signaling from latent membrane protein 1.

C W Dawson1, J H George, S M Blake, R Longnecker, L S Young.   

Abstract

The frequent coexpression of the EBV-encoded latent membrane proteins LMP1 and LMP2A/B in virus-associated tumors suggests that these two proteins may cooperate in the transformation process. While LMP2A is unable to directly activate the NF-kappaB and AP-1 pathways, we found that coexpression of LMP2A with LMP1 resulted in a significant enhancement of LMP1-mediated activation of these pathways. This enhancement was found to be critically dependent on the tyrosine residues present within the ITAM motif (Y74/Y85) and, to a lesser extent, the tyrosine at position 112 (Y112). Subsequent analysis revealed that LMP2A is able to stabilize and modulate the turnover of LMP1 by extending its half-life. This ability does not require a direct physical interaction between the two proteins but rather, results from an indirect effect of LMP2A on the turnover of the LMP1 protein. This study highlights an important role for LMP2A as a modulator of LMP1 activity in epithelial cells. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689042     DOI: 10.1006/viro.2001.1142

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  23 in total

Review 1.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

2.  Minimal protein domain requirements for the intracellular localization and self-aggregation of Epstein-Barr virus latent membrane protein 2.

Authors:  Monica Jo Tomaszewski-Flick; David T Rowe
Journal:  Virus Genes       Date:  2007-06-13       Impact factor: 2.332

3.  Mouse model for acute Epstein-Barr virus infection.

Authors:  Tristan Wirtz; Timm Weber; Sven Kracker; Thomas Sommermann; Klaus Rajewsky; Tomoharu Yasuda
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-16       Impact factor: 11.205

4.  The Epstein-Barr virus-encoded LMP2A and LMP2B proteins promote epithelial cell spreading and motility.

Authors:  Michael D Allen; Lawrence S Young; Christopher W Dawson
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Epstein-barr virus latent membrane protein 2B (LMP2B) modulates LMP2A activity.

Authors:  Mark Rovedo; Richard Longnecker
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

6.  Mouse model of Epstein-Barr virus LMP1- and LMP2A-driven germinal center B-cell lymphoproliferative disease.

Authors:  Takeharu Minamitani; Yijie Ma; Hufeng Zhou; Hiroshi Kida; Chao-Yuan Tsai; Masanori Obana; Daisuke Okuzaki; Yasushi Fujio; Atsushi Kumanogoh; Bo Zhao; Hitoshi Kikutani; Elliott Kieff; Benjamin E Gewurz; Teruhito Yasui
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-28       Impact factor: 11.205

7.  Augmented latent membrane protein 1 expression from Epstein-Barr virus episomes with minimal terminal repeats.

Authors:  Allison M Repic; Mingxia Shi; Rona S Scott; John W Sixbey
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

8.  EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression.

Authors:  Ilaria Guasparri; Darya Bubman; Ethel Cesarman
Journal:  Blood       Date:  2008-01-29       Impact factor: 22.113

9.  SYK interaction with ITGβ4 suppressed by Epstein-Barr virus LMP2A modulates migration and invasion of nasopharyngeal carcinoma cells.

Authors:  X Zhou; L Matskova; L-S Z Rathje; X Xiao; G Gish; M Werner; I Ignatyev; N Yu; W Zhao; F Tian; B Hou; Z Zhang; T Pawson; F Chen; I Ernberg
Journal:  Oncogene       Date:  2014-12-22       Impact factor: 9.867

10.  The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation.

Authors:  K M Shah; S E Stewart; W Wei; C B J Woodman; J D O'Neil; C W Dawson; L S Young
Journal:  Oncogene       Date:  2009-08-31       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.